ISSN: 1948-593X

Open Access

Pharmacological Studies on Respiratory Illness Organ of the Future

Natasha Gabriel*

Institute of Polymer Chemistry, Johannes Kepler University Linz, Austria

Description

Organ-on-a-chip models have been constructed and studied extensively. They are microfluidic devices that imitate the cellular architecture and physiological milieu of an organ. The chips can be customised to accommodate illness situations in a variety of organs. When compared to traditional in vitro models, lung-on-a-chip models produce a more realistic reflection. Lungon-a-chip is a micro-engineered cell culture system that mimics the 3D microarchitecture and microenvironment, breathing movements, and key physiological activities of the human lung, with applications in physiology, disease aetiology, toxicological investigations, and drug screening.

The first model was created utilising soft lithography-based microfabrication techniques as a polymer polydimethylsiloxane (PDMS) lung-on-a-chip model. A thin (10 mm) flexible, microporous, extracellular matrix (ECM)-coated membrane separated the upper and bottom microchannels in this model. Micro milling and solvent bonding techniques were used to develop the thermoplastic process. The lung airway milieu, as well as interactions between smooth muscle cells (SMCs), epithelial cells (ECs), and supporting ECM, were all replicated on the chip. 3D cell bioprinting was used to create an airway-on-a-chip model with a vascular network. Polycaprolactone (PCL), lung fibroblasts (LFs) bioink, endothelial cells bioink, and PDMS were employed in the vascular platform (VP). The VP was 3D printed directly from a cell-laden decellularized extracellular matrix (dECM) bioink, with a central reservoir and two lateral reservoirs for EC and LF bioinks.

For simulating physiological functions within chips, researchers have devised a range of models based on the experimental requirements. This also increased the production of pulmonary surfactants, which are important for maintaining the alveolar-capillary interface. In comparison to cells cultivated in liquid medium, this method resulted in higher electrical resistance across the distinct tissue layers, improved structural integrity, and normal barrier permeability. Organs-on-chip models are expected to be used in toxicity assessment in the near future, perhaps replacing or lowering the requirement for animal experiments. Researchers employed their microdevice to conduct toxicological research on the effects of nanoparticle exposure on the lungs.

The alveolar epithelium was exposed to silica nanoparticles, which activated the underlying endothelium and raised the amount of Intercellular Adhesion Molecule-1 (ICAM-1) expression. In the case of Cystic Fibrosis, germs infiltrate the lungs, producing inflammation and eventually respiratory failure. Detailed pathogenic mechanisms, on the other hand, are still unknown. As a result, Cystic Fibrosis (CF) has only been simulated on these chip models a few times. Lung-on-a-chip models can help fill the gap between disease-drug studies and accurate drug identification. In vitro studies of complex processes

*Address for Correspondence: Natasha Gabriel, Institute of Polymer Chemistry, Austria, Johannes Kepler University Linz, E-mail: Gabriel.nat@jku.at

Copyright: © 2022 Gabriel N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 04 May, 2022, Manuscript No.JBABM-22-66709; Editor Assigned: 06 May, 2022, PreQC No. P-66709; Reviewed: 18 May, 2022, QC No. Q-66709; Revised: 23 May, 2022, Manuscript No .R-66709; Published: 30 May, 2022, DOI: 10.37421/1948-593X.2022.14.328

will be aided by these models. With the increasing societal and economic burden of lung diseases and drugs, lung-on-a-chip might become a growing platform for identifying new and possibly optimal therapies for individuals, in addition to improving the patient's health state. It reduces pharmaceutical companies' and researchers' reliance on traditional in vitro and animal models, which are time-consuming, expensive, and occasionally unreliable.

Within three-dimensional (3D) structures, cells of various origins and phenotypes interact with one another to form functioning tissues and organs in the human body. Most in vitro models, on the other hand, are two-dimensional (2D) and so do not accurately represent the fundamentally complex nature of tissues and organs. As a result, traditional 2D models fail to accurately represent the structural, mechanical, and functional features of human tissue. In most 2D cell culture models, for example, just one cell type is cultivated on petri dishes or well plates, which does not reproduce the in vivo cellular milieu where cells interact with one another. In these models, monoculture influences cell shape, cell division mode, gene expression, cellular secretions, and physiological functioning [1-5].

Acknowledgement

None.

Conflict of Interest

The author has no conflict of interest towards the article.

References

- Clapp, Naomi, Augustin Amour, Wendy C. Rowan and Pelin L. Candarlioglu. "Organ-on-chip applications in drug discovery: an end user perspective." *Biochem* Soc Trans 49 (2021): 1881-1890.
- O'Leary, Cian, Jennifer L. Gilbert, Shirley O'Dea, Fergal J. O'Brien, and Sally-Ann Cryan. "Respiratory tissue engineering: Current status and opportunities for the future." *Tissue Eng Part B Rev* 21 (2015): 323-344.
- Mishra, Bhuwan B. and Vinod K. Tiwari. "Natural products: an evolving role in future drug discovery." *Eur J Med Chem* 46 (2011): 4769-4807.
- Beloqui, Ana, María Ángeles Solinís, Alicia Rodríguez-Gascón and António J. Almeida, et al. "Nanostructured lipid carriers: Promising drug delivery systems for future clinics." Nanomed Nanotechnol Biol Med 12 (2016): 143-161.
- Sommer, Natascha, Hossein A. Ghofrani, Oleg Pak and Sebastien Bonnet, et al. "Current and future treatments of pulmonary arterial hypertension." *Br J Pharmacol* 178 (2021): 6-30.

How to cite this article: Gabriel, Natasha. "Pharmacological Studies on Respiratory Illness Organ of the Future." J Bioanal Biomed 14 (2022): 328.